Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Paclitaxel + Pertuzumab + pUMVC3-IGFBP2-HER2-IGF1R vaccine + Trastuzumab|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Paclitaxel||Taxol||7-Epipaclitaxel||Antimicrotubule Agent 12 BCL2 Family Inhibitor 6||Taxol (paclitaxel) binds to tubulin to inhibit microtubule disassembly, which results in decreased cell division, and also binds to the anti-apoptotic factor Bcl-2, promoting apoptosis (NCI Drug Dictionary).|
|Pertuzumab||Perjeta||2C4 Antibody||HER2 (ERBB2) Antibody 39||Perjeta (pertuzumab) is a monoclonal antibody that binds ERBB2 (HER2) to prevent dimerization and subsequent HER signaling, thereby resulting in apoptosis and tumor growth inhibition (PMID: 15699478). Perjeta (pertuzumab) is FDA approved in combination with Herceptin (trastuzumab) and Taxotere (docetaxel) for patients with ERBB2 (HER2)-positive breast cancer and in combination with Herceptin (trastuzumab) and chemotherapy as neoadjuvant treatment for patients with ERBB2 (HER2)-positive breast cancer (FDA.gov).|
|Trastuzumab||Herceptin||Anti HER2||HER2 (ERBB2) Antibody 39||Herceptin (trastuzumab) is a monoclonal antibody, which binds ERBB2 (HER2) to induce tumor cellular cytotoxicity (PMID: 17611206). Herceptin (trastuzumab) is FDA approved for HER2-overexpressing (or amplification) breast cancer, gastric adenocarcinoma, and gastroesophageal junction adenocarcinoma (FDA.gov).|
|pUMVC3-IGFBP2-HER2-IGF1R vaccine||WOKVAC vaccine|WOKVAC||pUMVC3-IGFBP2-HER2-IGF1R (WOKVAC) vaccine is a plasmid-based vaccine containing sequences for IGFBP2, ERBB2 (HER2), and IGF1R, which potentially induces immune response against tumors expressing these proteins (Cancer Res February 15 2017 (77) (4 Supplement) OT3-01-03).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT04329065||Phase II||Paclitaxel + Pertuzumab + pUMVC3-IGFBP2-HER2-IGF1R vaccine + Trastuzumab||Concurrent WOKVAC Vaccination, Chemotherapy, and HER2-Targeted Monoclonal Antibody Therapy Before Surgery for the Treatment of Patients With Breast Cancer||Not yet recruiting|